No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a comprehensive healthcare enterprise, operating across Mainland China and international markets. Its principal activities include the research, development, production, and commercialization of pharmaceutical products. The company focuses on significant therapeutic domains such as oncology, immunology, metabolic disorders, gastrointestinal health, and central nervous system conditions. In addition to its drug offerings, Fosun Pharma provides medical devices and diagnostic solutions. Its multifaceted operations are organized into five key segments: pharmaceutical manufacturing, medical devices and diagnostics, healthcare services, pharmaceutical distribution and retail, and other business initiatives. This scope extends to managing healthcare facilities and hospitals, as well as the wholesale and retail distribution of medicines. The company was founded in 1994 and is headquartered in Shanghai, China.
www.fosunpharma.comNo one on the platform currently holds 2196.HK.
No tracked institution reports a position in 2196.HK as of their last filing.
No one on the platform has traded 2196.HK yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 2.8% | 6.9% | 8.1% | — | — | — |
| Rev. Growth % | -1.6% | 5.9% | ||||
| Profit Margin % | 8.1% | 8.2% | 11.2% | |||
| Free Cash Flow Margin % | 1.9% | -1.8% | -1.5% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $45.2B | +10.2% | $1.51 | $1.41–$1.59 | — | 5 |
| 2027 | $46.3B | +2.4% | $1.71 | $1.58–$1.91 | — | 5 |
| 2028 | $49.2B | +6.4% | $1.96 | $1.88–$2.05 | — | 2 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 6 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-25 | $0.35 | $0.75 | +111.5% |
| 2026-04-27 | $0.35 | $0.38 | +5.9% |
| 2026-03-24 | $0.29 | $0.69 | +138.1% |
| 2025-10-29 | $0.30 | $0.34 | +12.9% |
| 2025-08-26 | $0.27 | $0.70 | +155.2% |
| 2025-04-29 | $0.30 | $0.31 | +4.6% |
| 2025-03-25 | $0.30 | $0.30 | -0.7% |
| 2024-10-29 | $0.30 | $0.29 | -3.3% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 2196.HKShanghai Fosun Pharmaceutical (Group) Co., Ltd. | $16.93 | -1.11% | $63.4B | — |
| 0512.HKGrand Pharmaceutical Group Limited | $4.91 | +0.51% | $17.2B | — |
| 0867.HKChina Medical System Holdings Limited | $10.90 | -2.07% | $26.5B | — |
| 0874.HKGuangzhou Baiyunshan Pharmaceutical Holdings Company Limited | $13.20 | -0.68% | $32.8B | — |
| 1093.HKCSPC Pharmaceutical Group Limited |
| $8.70 |
| -1.86% |
| $99.2B |
| — |
| 1099.HKSinopharm Group Co. Ltd. | $15.09 | -1.69% | $47.1B | — |
| 1530.HK3SBio Inc. | $16.03 | -1.17% | $40.1B | — |
Source: Financial Modeling Prep · peers by sector/industry